|
Back to Home » May 2018 News » Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder |
Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder |
May 28, 2018
PLYMOUTH MEETING, Pa., May 28, 2018 /PRNewswire/ -- Braeburn announces the resubmission of the New Drug Application (NDA) for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly depot injection for the treatment of opioid use disorder (OUD). The resubmission is in...
Source URL: https://www.prnewswire.com/news-releases/braeburn-resubmits-new-drug-application-for-cam2038-for-opioid-use-disorder-300655354.html
|
|
|
|
